PARADIGM: Panitumumab plus mFOLFOX6 in RAS wt mCRC

(2:43)

PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC

(2:42)

PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC

(1:28)

How will the PARADIGM trial change the mCRC treatment landscape?

(1:5)

Phase 3 PARADIGM Trial Review | Anwaar Saaeed, MD | ASCO22 Colorectal Cancer Updates

(55)

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

(2:50)

Panitumumab + mFOLOFOX6 as the new standard of care for RAS WT metastatic colorectal cancer

(33)

Panitumumab significantly improves OS vs bevacizumab + mFOLFOX6 in patients with RAS WT and left...

(6:12)

Expert Report on panitumumab for first line treatment of RAS wild type mCRC from ASCO 2022

(7:28)

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

(3:36)

PARADIGM: acquired gene alterations and progressive disease in CRC

(1:2)

Anti-EGFR therapy for RAS wild-type left-sided colorectal cancer

(2:10)

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC

(2:40)

Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in Colorectal Cancer

(57)

First- and Later-line Use of Panitumumab in Metastatic Colorectal Cancer

(9:)

PANAMA: addition of maintenance panitumumab does not affect QoL in mCRC

(2:35)

Panitumumab, Regorafenib, and Ziv-aflibercept in Metastatic Colorectal Cancer

(11:36)

Panitumumab data presented at ESMO 2016: depth of response and selecting the right patients

(1:37)

PANAMA trial: Maintenance therapy with 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

(5:50)

Panitumumab triplet therapy in colorectal cancer

(6:32)

“இஸ்லாத்தில் ஒழுக்கம் உள்ளவனே உயர்ந்தவன்” - டாக்டர் கேவிஎஸ் ஹபீப் முகமது! #q7tvnews

(1:29)

காட்டிக் கொடுத்தது, மோசமான முன்னுதாரணம்!. தூத்துக்குடி சம்பவத்தில் சொன்னவர்தானே!. கடந்துபோக வேண்டுமா

(1:51)